Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.
Menu

Researcher Publications

Edmund C. Lattime, PhD

Selected Publications

  • Nikitczuk KP, Lattime EC, Schloss RS and Yarmush ML. Analysis of dendritic cell stimulation utilizing a multi-faceted nanopolymer delivery system and the immune modulator 1-methyl tryptophan. Nano Life, 1:1(3-4):239-250, 2010.
  • Moloughney JG, Monken CE, Zhang H, Thomas JD, Lattime EC and Jin S. Vaccinia virus leads to ATG12-ATG3 conjugation and deficiency in autophagosome formation. Autophagy, 7(12):1434-47, 2011.
  • Nikitczuk KP, Schloss RS, Yarmush ML and Lattime EC. PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival. J Cancer Ther, 4(1):280-290, 2013.
  • de Vries CR, Poplin E, Weiss RE, August DA, Gabriel E, DiPaola RS, and Lattime EC Poxvirus-based strategies for combined vaccine and tumor microenvironment manipulation In: Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation, third edition, edited by EC Lattime and SL Gerson. San Diego: Academic Press, 241-257, 2013.
  • de Vries CR, Monken CE, and Lattime EC. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy. Cancer Gene Ther.22(3):154-62, 2015..
  • de Vries CR, Monken CE, and Lattime EC. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy. Cancer Gene Therapy, 22(3):154-162, 2015.
  • DiPaola RS, Chen Y-H, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley J, Arlen PM, Butterfield LH, Wilding G. A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802. Eur. Urol. (Epub ahead of print), 2015.
  • Kohlhapp FJ, Huelsmann EJ, Lacek AT, Schenkel JM, Lusciks J, Broucek JR, Goldufsky JW, Hughes T, Zayas JP, Dolubizno H, Sowell RT, Kuehner R, Burd S, Kubasiak JC, Nabatiyan A, Marshall S, Bommareddy PK, Li S, Newman JH, MonkenCE, Shafikhani S, Marzo AL, Guevara-Patino JA, Lasfar A, Thomas PG, Lattime EC, Kaufman HL, Zloza A. Non-oncogenis acute viral infections disrupt anti-cancer responses and lead to accelerated cancer-specific host death. Cell Reports, 17:957-965, 2016.
  • Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman H, Lattime EC, Mehnert J, Sullivan R, Lovly CM, Sosman J, Johnson DB, Bhanot G, Ganesan S. Identifying a clinically applicable mutation burden threshold as a biomarker of response to immune checkpoint therapy of solid tumors. J. Clin. Oncol Precision Oncol. 1:1-13, 2017
  • Poillet-Perez L, Xie X, Zhan L, Sharp D, Hu ZS, Zheng H, Lu W, Bosenberg MW, Mehnert J, Guo J, Lattime E, Rabinowitz JD, White E. Autophagy maintains tumor growth through circulating arginine. Nature 563: 569-573, 2018.
  • Portal DE*, Weiss RE*, Wojtowicz M, Mansour A, Monken C, Mehnert JM, Aisner JA, Kane M, Nishioka J, Aisner S, Peters S, Stein MN, Kim IY, Mayer TM, Shih W, Gulley J, Streicher H, Singer EA, Lattime EC. Phase I neoadjuvant study of intravesical recombinant Fowlpox-GM-CSF (rFGMCSF) or Fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma. Cancer Gene Therapy 27: 438-447, 2020 (Epub 2019)
  • Poillet-Perez L, Sharp DW, Yang Y, Ibrahim M, Bommareddy P, Laddha SV, Hu ZS, Vieth J, Bosenberg MW, Rabinowitz JD, Chan CS, Mehnert JM, Lattime EC, White E. Autophagy promotes growth of tumors with high mutational burden by inhibiting a T cell immune response. Nature Cancer (in press), 2020.

Return to member profile